Psychiatry 2007;4(5):21-23
by Elisa F. Cascade; Amir H. Kalali, MD; Jeffrey Lieberman, MD; John Hsiao, MD; Richard Keefe, PhD; and Scott Stroup, MD
Author Affiliations: Ms. Cascade is Vice President, Strategic Research and Safety, Quintiles Inc., Falls Church, Virginia; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles Inc., San Diego, California, and Professor of Psychiatry, University of California, San Diego; and Dr. Lieberman is the Lawrence E. Kolb Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons, Director of the New York State Psychiatric Institute, and the Lieber Chair of the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia University, New York, New York; Dr. Hsiao is with the adult treatment and preventive interventions branch of the division of services and interventions research at NIMH in Bethesda, Maryland; Dr. Keefe is Associate Professor of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina; and Dr. Stroup is Associate Professor of Psychiatry at the University of North Carolina at Chapel Hill and Adjunct Associate Professor of Social Medicine.
Abstract
We investigated the share of branded and generic antipsychotics before and after the publication of the CATIE results in September, 2005. According to our data, the publication of the CATIE results has had very little impact on new patient starts. To determine the impact of CATIE on use of olanzapine (Zyprexa®) subsequent to first line therapy, we also examined product share for switch/add patients. We found that since the publication of the CATIE results, the use of olanzapine has stabilized, following a decline subsequent to first line therapy, and may potentially be growing very slowly. An expert commentary is provided on the data.
Key words: antipsychotic, CATIE, schizophrenia, olanzapine, zyprexa
Psychiatry 2007;4(5):21-23
Read the rest of this article »
Popularity: unranked [?]